Please assess the completion status of the following clinical trial:

Trial Title: Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* persistently elevated serum aminotransferase levels~* diffusely echogenic liver on imaging studies suggestive of fatty liver~* biopsy consistent with the diagnosis of NAFLD~Exclusion Criteria:~* hepatic virus infections (HCV RNA-PCR negative)~* Hepatitis A, B, C, D, E and G~* cytomegalovirus and Epstein-Barr virus~* alcohol consumption~* history of parenteral nutrition~* use of drugs known to induce steatosis or to affect body weight and carbohydrate metabolism~* autoimmune liver disease, metabolic liver disease, Wilson's disease, and a-1-antitrypsin-associated liver disease were ruled out using standard clinical, laboratory and histological criteria

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- DHA250 (Type: EXPERIMENTAL): DHA 250 mg/kg/d plus lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
- DHA500 (Type: EXPERIMENTAL): DHA 250 mg/kg/d plus lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
- PLA (Type: PLACEBO_COMPARATOR): placebo and lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].

Based on this trial design, predict the completion outcome and termination type (if applicable).